Technical Documents

Press Hits and Civil Society Statements

Actions in Ecuador

"There is, in our law, what is called compulsory licensing.  I, as President, can order that we issue a compulsory license for Brand X, so this medicine can be copied to make generics, and the people have access to this medicine, to health, to a cure for their illness.  And this is exactly what we are going to begin to do..."

"This is our vision of intellectual property.  It's not a mechanism to enrich the pharmaceutical or agrochemical companies.  It's a mechanism for development for the people." 

-- Rafael Correa Delgado, President of the Republic of Ecuador


October 2, 2014 - Public Citizen Chart summarizing history of compulsory licensing in Ecuador

September 2, 2014 - One Step Forward, One Step Back – Ecuador issues new, pro-health compulsory licenses, but signs harmful trade agreement with the European Union (available in Spanish here)

November 2012: Ecuador issues second license to expand access to HIV/AIDS treatments

See Public Citizen's full statement on Ecuador's compulsory license for abacavir+lamivudine.

En Español

On November 12, 2012, Ecuador issued a second license to promote cost-cutting generic competition for life-saving HIV/AIDS treatments. The government issued the license to Acromax, a firm based in Ecuador, to import and locally produce Glaxo's patented abacavir+lamivudine combination (ABC+3TC)a second-line treatment in Ecuador. This will enable the government to further expand access to more affordable treatments and is intended to facilitate local production of the product.

Ecuador has become a leader in the fight for access to affordable medicines. In 2009, President Correa declared access to priority medicines affecting the health of the Ecuadorean population to be a matter of public interest, effectively clearing the way for generic competition. The President declared: “compulsory licenses may be granted for patents on any human use medicine that may be necessary for treatment,” inaugurating a licensing protocol. President Correa spoke on live television for several minutes on the specific subject of compulsory licensing. In 2010, the country issued its first license for ritonavir, a component of the HIV/AIDS treatment Kaletra, cutting bid prices by about 27%.

See translated summary of the most recent compulsory licensing order in English


See the statement from Rene Ramirez, Ecuardor's Minister of Higher Education, Science, Technology and Innovation for the global day of action on November 10, 2011.


Essential Action / Public Citizen documents

October 2, 2014 - Public Citizen Chart summarizing history of compulsory licensing in Ecuador
September 2, 2014 - One Step Forward, One Step Back – Ecuador issues new, pro-health compulsory licenses, but signs harmful trade agreement with the European Union (available in Spanish here)
November 20, 2012-Public Citizen statement: Ecuador licenses a second life-saving HIV/AIDS treatment to local pharmaceutical firm
(En Español)

May 10, 2011-Leaked Cables Show U.S. Tried, Failed, to Organize against Ecuador Compulsory Licensing
May, 2010-Press Release: Unsupported claims in ECAT's submission to USTR on Ecuador, intellectual property and ATPA
April 22, 2010-Press Release: By Authorizing Generic Competition, Ecuador Cuts Cost of Key HIV/AIDS Drug
March 3, 2010- Press Release: Special 301 and Ecuador's TRIPS-Compliant Protocol on Access to Medicines and Compulsory Licensing
February, 2010-Updates and Information on Compulsory Licensing in Ecuador - Essential Action 2009-2010
February 16, 2010-Letter to USTR from Global Access to Medicines Director, Peter Maybarduk: USTR-2010-003 (2010 Special 301 Review: Identification of Countries under Section 182 of the Trade ACt of 1974
Essential Actions Corrections to Media Reports on Ecuador's Presidential Declaration on Compulsory Licensing
November, 2009-Essential Action's Clarifications concerning Ecuador's Declaration on Compulsory Licensing
October 26, 2009-Essential Action's Backgrounder on Ecuador's Presidential Declaration on Access to Medicines and Compulsory Licenses
August, 2009 - Ecuadorian Institute for Intellectual Property: Administrative Guide for the issuance of compulsory licenses for pharmaceutical products in Ecuador
November 25, 2008 - Civil Society Letter to Dr. Gutierrez: Proposal to increase access to HIV treatment in Ecuador



Wikileaks cables

Read Wikileaks cables from U.S. Embassy personnel to the U.S. Department of State, showing the United States, multinational pharmaceutical companies, and three Ministers within the government shared information and worked to undermine Ecuador's compulsory licensing policy.



HIV/AIDS Treatment Coverage in Ecuador


      Number of patients receiving                               Percent of patients receiving ARV

        ARV treatment,  2008-2010                                treatments by line of regimen, 2010

 

 


        
Percent of patients receiving ARV treatments by type of treatment, 2010

       

Source: Organización Panamericana de la Salud, "Tratamiento antirretroviral bajo la lupa: un análisis de salud pública en Latinoamérica y el Caribe, Ecuador", 2012.



History of Compulsory Licensing in Ecuador

Read about the development of a compulsory licensing protocol in Ecuador

See timeline on Ecuador's compulsory licensing





Return to the Kaletra Campaign Homepage


Copyright © 2014 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.

 

To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.